Please note: The University of Texas Health Science Center at San Antonio will now be called "UT Health San Antonio."

Search Program Faculty/Research

Babatunde “Kay” Oyajobi, M.B.,B.S, Ph.D., M.B.A.

Img 8252

RESEARCH

Dr. Oyajobi's lab conducts studies aimed at understanding the pathogenesis of cancer-induced bone diseases and specifically, the multiple myeloma-associated bone disease. We are particularly interested in the translation of novel insights into the biology of multiple myeloma-induced bone disease into therapies for patients and employ a variety of complementary in vitro and in vivo approaches. To evaluate efficacy of novel therapeutic agents, we utilize primarily the Radl 5T model of myeloma which replicates many of the features seen in the human disease. In this model, when murine 5TGM1 myeloma cells genetically engineered to express either green fluorescent protein or luciferase are injected intravenously in naïve syngeneic C57BL/kaLwRijHsd mice, they home to the skeleton where they form tumors in the medullary cavities.

Selected Publications

McDonald MM, Reagan MR, Youlten SE, Mohanty ST, Seckinger A, Terry RL, Pettitt JA, Simic MK, Cheng TL, Morse A, Le LMT, Abi-Hanna D, Kramer I, Falank C, Fairfield H, Ghobrial IM, Baldock PA, Little DG, Kneissel M, Vanderkerken K, Bassett JHD, Williams GR, Oyajobi BO, Hose D, Phan TG, Croucher PI. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma. Blood. 2017 Jun 29; 129(26): 3452-3464. PMID: 28515094

Nyman JS, Merkel AR, Uppuganti S, Nayak B, Rowland B, Makowski AJ, Oyajobi BO, Sterling JA. Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease. Bone. 2016 Oct; 91: 81-91. PMID: 27423464

Sharma R, Williams PJ, Gupta A, McCluskey B, Bhaskaran S, Muñoz S, Oyajobi BO. A dominant-negative F-box deleted mutant of E3 ubiquitin ligase, β-TrCP1/FWD1, markedly reduces myeloma cell growth and survival in mice. Oncotarget. 2015 Aug 28; 6(25): 21589-21602. PMID: 26009993

Medina EM, Oberheu K., Polusani SR, Ortega V, Velagaleti GVN, Oyajobi BO. PKA/AMPK signaling in relation to the anti-proliferative effect of adiponectin on multiple myeloma.  Leukemia. 2014 Oct;28(10):2080-2089.  PMID 24646889.

Dairaghi DJ, Oyajobi BO, Gupta A, McCluskey B, Miao S, Powers JP, Seitz LC, Wang Y, Zeng Y, Zhang P, Schall TJ, Jaen JC. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease. Blood. 2012 Aug 16;120(7):1449-57. [Highlighted in (i) ‘Inside Blood‘ Commentary, page 1351 of same issue; (ii) Science-Business eXchange SciBX 5(23); (iii) BoneKEy Reports 1:168

Oyajobi BO, Muñoz S, Kakonen R, Williams PJ, Gupta A, Wideman CL, Story B, Grubbs B, Armstrong A, Dougall WC, Garrett IR, Mundy GR. Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther. 2007 Jun;6(6):1701-8. (Featured in “Molecular Cancer Therapeutics Highlights" of same issue)

Professor

Cell Systems and Anatomy

Education

MBA, University of Texas at Austin, 2007

Ph.D. Human Metabolism & Clinical Biochemistry; University of Sheffield, England 1992

M.S., Clinical Biochemistry; University of Leeds, England 1986

MBBS, (M.D. equivalent) University of Lagos, Nigeria 1983

Contact

Email: OYAJOBI@UTHSCSA.EDU

Phone: (210) 567-0909


Research Profile
More Info...